Table 3. Seropositivity of polyomaviruses and association with lung cancer stratified by participating study.
|
Cases |
Controls |
|||||
|---|---|---|---|---|---|---|
| n | % | n | % | Odds ratio (95% CI) | P-value | |
|
Janus | ||||||
| JCV (VP1) | 75 | 59.5 | 77 | 62.1 | 0.90 (0.54–1.49) | 0.68 |
| BKV (VP1) | 105 | 83.3 | 106 | 85.5 | 0.85 (0.43–1.68) | 0.64 |
| KI (VP1) | 113 | 89.7 | 116 | 93.6 | 0.60 (0.24–1.50) | 0.28 |
| WU (VP1) | 119 | 94.4 | 118 | 95.2 | 0.86 (0.28–2.65) | 0.8 |
| TSV (VP1) | 100 | 79.4 | 99 | 79.8 | 0.97 (0.52–1.80) | 0.93 |
| MCV (VP1) | 84 | 66.7 | 79 | 63.7 | 1.14 (0.68–1.92) | 0.62 |
| HPyV6 (VP1) | 97 | 77.0 | 98 | 79.0 | 0.89 (0.49–1.62) | 0.7 |
| HPyV7 (VP1) | 69 | 54.8 | 78 | 62.9 | 0.71 (0.43–1.18) | 0.19 |
| HPyV10 (VP1) | 126 | 100.0 | 124 | 100.0 | a | |
|
NYU-WHS | ||||||
| JCV (VP1) | 34 | 53.1 | 35 | 54.7 | 0.94 (0.47–1.88) | 0.86 |
| BKV (VP1) | 55 | 85.9 | 57 | 89.1 | 0.75 (0.26–2.16) | 0.59 |
| KI (VP1) | 57 | 89.1 | 57 | 89.1 | 1 (0.33–3.03) | 1.00 |
| WU (VP1) | 56 | 87.5 | 63 | 98.4 | 0.11 (0.01–0.92) | 0.04 |
| TSV (VP1) | 42 | 65.6 | 44 | 68.8 | 0.87 (0.42–1.82) | 0.71 |
| MCV (VP1) | 51 | 79.7 | 49 | 76.6 | 1.20 (0.52–2.78) | 0.67 |
| HPyV6 (VP1) | 49 | 76.6 | 47 | 73.4 | 1.18 (0.53–2.63) | 0.68 |
| HPyV7 (VP1) | 37 | 57.8 | 36 | 56.3 | 1.07 (0.53–2.15) | 0.86 |
| HPyV10 (VP1) | 64 | 100.0 | 63 | 98.4 | a | |
|
SWHS | ||||||
| JCV (VP1) | 156 | 75.4 | 151 | 73.3 | 1.11 (0.72–1.73) | 0.63 |
| BKV (VP1) | 193 | 93.2 | 188 | 91.3 | 1.32 (0.64–2.73) | 0.45 |
| KI (VP1) | 183 | 88.4 | 182 | 88.4 | 1.01 (0.55–1.84) | 0.99 |
| WU (VP1) | 206 | 99.5 | 204 | 99.0 | 2.02 (0.18–22.45) | 0.57 |
| TSV (VP1) | 164 | 79.2 | 163 | 79.1 | 1.01 (0.63–1.62) | 0.98 |
| MCV (VP1) | 127 | 61.4 | 138 | 67.0 | 0.78 (0.52–1.17) | 0.23 |
| HPyV6 (VP1) | 156 | 75.4 | 169 | 82.0 | 0.67 (0.42–1.08) | 0.1 |
| HPyV7 (VP1) | 148 | 71.5 | 146 | 70.9 | 1.03 (0.67–1.58) | 0.89 |
| HPyV10 (VP1) | 199 | 96.1 | 201 | 97.6 | 0.62 (0.20–1.92) | 0.41 |
|
SCHS | ||||||
| JCV (VP1) | 88 | 77.2 | 86 | 75.4 | 1.10 (0.60–2.03) | 0.76 |
| BKV (VP1) | 102 | 89.5 | 105 | 92.1 | 0.73 (0.29–1.80) | 0.49 |
| KI (VP1) | 81 | 71.1 | 90 | 79.0 | 0.65 (0.36–1.20) | 0.17 |
| WU (VP1) | 109 | 95.6 | 107 | 93.9 | 1.43 (0.44–4.63) | 0.56 |
| TSV (VP1) | 85 | 74.6 | 81 | 71.1 | 1.19 (0.67–2.14) | 0.55 |
| MCV (VP1) | 41 | 36.0 | 47 | 41.2 | 0.80 (0.47–1.37) | 0.42 |
| HPyV6 (VP1) | 91 | 79.8 | 85 | 74.6 | 1.35 (0.72–2.51) | 0.34 |
| HPyV7 (VP1) | 76 | 66.7 | 72 | 63.2 | 1.17 (0.68–2.01) | 0.58 |
| HPyV10 (VP1) | 103 | 90.4 | 108 | 94.7 | 0.52 (0.19–1.46) | 0.21 |
|
Xuanwei study | ||||||
| JCV (VP1) | 153 | 73.2 | 170 | 81.3 | 0.63 (0.39–1.00) | 0.05 |
| BKV (VP1) | 160 | 76.6 | 161 | 77.0 | 0.97 (0.62–1.53) | 0.91 |
| KI (VP1) | 190 | 90.9 | 186 | 89.0 | 1.24 (0.65–2.35) | 0.52 |
| WU (VP1) | 208 | 99.5 | 207 | 99.0 | 2.01 (0.18–22.33) | 0.57 |
| TSV (VP1) | 181 | 86.6 | 181 | 86.6 | 1 (0.57–1.76) | 1 |
| MCV (VP1) | 113 | 54.1 | 101 | 48.3 | 1.26 (0.86–1.85) | 0.24 |
| HPyV6 (VP1) | 58 | 27.8 | 68 | 32.5 | 0.80 (0.52–1.21) | 0.29 |
| HPyV7 (VP1) | 23 | 11.0 | 19 | 9.1 | 1.24 (0.65–2.35) | 0.52 |
| HPyV10 (VP1) | 193 | 92.3 | 197 | 94.3 | 0.73 (0.34–1.59) | 0.44 |
Abbreviations: BKV=BK virus; CI=confidence interval; HPyV6=human polyoma virus 6; HPyV7=human polyoma virus 7; HPyV10=human polyoma virus 10; JCV=JC virus; MCV=Merkel cell polyoma virus; n=number; TSV=trichodysplasia spinulosa-associated polyoma virus.
Seropositivity for each polyomavirus VP1 defined as MFI⩾250 and MFI⩾400 for each TAg (except for MCV small TAg where seropositive if MFI⩾200).
a
Odds ratio cannot be calculated as 100% seropositivity for polyomavirus in cases.